Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
AI heavyweight Anthropic has appointed Novartis CEO Vas Narasimhan to its board of directors as the link between…
Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth
Novartis’ CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s…
Novartis profit beats estimates, signals return to growth
Novartis AG reported higher-than-expected profit last quarter as newer cancer medicines offset the ageing blockbuster Entresto’s generic hit,…
Novartis Profit Beats Estimates, Signals Return to Growth
Novartis AG reported higher-than-expected profit last quarter as newer cancer medicines offset the aging blockbuster Entresto’s loss of…
Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline
Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to…
Big Pharma Is Buying Growth. Novartis (NVS) Is Betting on Its Pipeline
Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to…
AI is helping speed up the timelines of drug discovery, Novartis CEO says
00:00 Speaker A You recently joined the board of Anthropic. Not going to ask you about that specifically,…
Novartis CEO pay soars 30% to $32M in 2025
Novartis CEO Vas Narasimhan saw his realized compensation swell by 30% in 2025, reaching 24.9 million Swiss francs…
Novartis CEO eyes 2026 growth despite record patent cliff
Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s…
Novartis CEO Narasimhan echoes call for EU drug pricing reform
Novartis CEO Vas Narasimhan says Europe needs a “complete rethink” of how it prices its drugs, warning that…
Switzerland-Based Novartis Breaks Ground on Radioligand Therapy Site in Denton » Dallas Innovates
Novartis breaks ground on its Denton radioligand therapy site. [Photo: Novartis] Swiss global pharmaceutical giant Novartis recently broke…
Novartis Profit, Sales Decline as Generic Competition Bites
Novartis AG’s profit fell more than estimated and sales unexpectedly declined in the first quarter as some of…